Summary for doctors
- Advanced endometrial cancer after platinum, especially pMMR [1].
- Most patients need a lenvatinib dose reduction [1].
Dose and schedule
Len/Pembro
Advanced endometrial cancer, after platinumEach drug’s schedule in the table
Advanced endometrial cancer, after platinum
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Lenvatinib | 20 mg | Oral | Daily |
| Pembrolizumab | 200 mg | IV | Every 3 weeks |
Evidence: KEYNOTE-775 (2022)
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- Control blood pressure before starting and check it weekly in the first month.
- Baseline urine protein, TSH and liver enzymes.
Monitoring and dose adjustment
- Hypertension, proteinuria, diarrhoea and fatigue: hold and reduce lenvatinib (14, 10, 8 mg).
- TSH, glucose, liver enzymes and creatinine at baseline and before each cycle; immune-related toxicity as in the immunotherapy toxicity lesson.
Main evidence
Show detailsHide
KEYNOTE-775: median overall survival 18.3 vs 11.4 months with chemotherapy of the physician's choice (in pMMR 17.4 vs 12.0) [1].
Related cancer types
Treatment regimens (physicians)
References
2 referencesShow all references, 1 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2LENVIMA (LENVATINIB) — Prescribing Information
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/lenvatinib-pembrolizumab-endometrial/